Busted Biotechs and Pricing Risk with Chris DeMuth Jr. – The Special Situations Report Episode #17

Episode Summary

Executive Summary: Chris Timo Jr. discusses his lifelong attraction to investing as a search for mispricings, his process of building an edge from primary sources and local knowledge, and how increasingly competitive markets have shifted event-driven investing toward more fundamental analysis. He also explains Rangeley Capital’s structure, sizing discipline, systemic-risk diversification, and his current interest in busted biotechs, Burford/YPF, and Keros Therapeutics.

Main Topics: Lifelong investment philosophy and motivation (Priority: 5/5): Chris describes investing as a creative, disciplined hunt for mispriced situations. He emphasizes curiosity, optimization, and the enjoyment of finding something the market has labeled incorrectly rather than following routine or conventional work. Research process: primary sources and local knowledge (Priority: 5/5): He stresses getting close to the source—SEC filings, management, customers, vendors, competitors, and experts with direct operating experience—rather than relying on market generalities or secondhand commentary. Rangeley Capital strategy and the evolution of special situations (Priority: 5/5): Rangeley is positioned as a value/event-driven investor across hedge funds and SMAs, with emphasis on mergers, spin-offs, rights offerings, special dividends, and other analyzable corporate actions. Chris explains how increasing competition and speed have made traditional arbitrage less scalable. Position sizing, Kelly criterion, and process discipline (Priority: 5/5): Chris explains that while he admired Kelly criteria, real-world portfolio management is constrained by uncertainty, research time, and the need to preserve flexibility. He prefers starting small, avoiding overcommitment, and sizing positions based on conviction and downside tolerance. Systemic risk and portfolio diversification (Priority: 4/5): He argues that successful investors and operators are often overconcentrated in the assets that created their wealth. He recommends a balancing allocation to reduce exposure to financial-system shocks, cyber risks, natural disasters, or other systemic disruptions. Current opportunity set: busted biotechs, Burford, and Keros (Priority: 5/5): With equity volatility, difficult financing, and skittish boards, Chris says busted biotechs are attractive because they often don’t require fresh capital and can be liquidated or monetized. He also outlines his bullish view on Burford’s Peterson/YPF claims and sees Keros as a close-call strategic review where shareholders should push for value realization. Behavioral caution: comfort, loyalty, and small-cap traps (Priority: 4/5): Chris warns that comfort with management or old ideas can be dangerous, and that small-cap cheapness can be a red flag when poor management or illiquidity explain the discount. He is increasingly skeptical of obvious small-cap treasure hunts unless governance and alignment are strong.

Key Arguments: Investing is best understood as a search for mispricings, not a formulaic exercise; the work is enjoyable only if it feels like a genuine hunt for errors in the market. Primary sources matter because financial statements alone can be misleading; understanding a business requires talking to the people closest to it and building a mosaic of evidence. Local knowledge is underrated: the most important edge often comes from narrow, specific expertise that insiders see as ordinary but outsiders miss. Traditional merger arbitrage has become more competitive and less scalable as information moved from days to minutes to milliseconds, forcing event investors to add a fundamental view. Good opportunities often disappear as they are discovered; when a strategy remains easy forever, it may not be a real edge. Position sizing should protect against error and preserve optionality; starting too large destroys flexibility, while too small leads to unproductive research effort. The goal is not to maximize certainty but to buy enough expected value at a discount that delays or adverse revisions still leave a good outcome. Systemic risks can wipe out financial-only concentration, so even successful investors should diversify into real assets or operating businesses to reduce tail risk. Busted biotechs are attractive in a tight-financing environment because they may be monetized or liquidated without needing new capital. Shareholders in biotech should actively pressure boards to monetize or return capital rather than letting management continue uneconomic science projects. Burford’s value is largely tied to the Peterson/YPF claims, which Chris views as valuable but slow-moving and dependent on settlement rather than force. Small-cap cheapness can be a false signal; illiquidity and poor governance may justify the discount rather than create a bargain.

Data Points: Podcast episode: Episode 17 - Special Situations Report, first guest on the podcast Research depth target: 60–70% - Chris says he tries to get this far through understanding before speaking to experts Years following Chris's work: ~10 years - Host says he has followed Chris's work for the better part of a decade Position size starting point: <1% to 1–2% - Chris says starting too small is unproductive, but too large destroys flexibility Preferred portfolio concentration: 10 positions or fewer is ideal - Chris says 10 would be lovely, though he often ends up with more Risk tolerance goal: Able to be wrong hundreds of times a year - Chris says sizing should allow many mistakes without ruining the year Implication sizing heuristic: ~10% allocation to the other side - Chris suggests a small balancing allocation to reduce systemic risk concentration Historical strategy shift: Merger arb good in the 1980s; index arb good in the 1980s/1990s/early 2000s - He says these strategies became more competitive over time Expected review horizon: Days to weeks to months - He says busted biotechs are attractive in the current near-term environment Example spread threshold: Less than 50 cents on the dollar - He wants deep discounts in busted biotech situations Potential recovery pricing: 75–80 cents on the dollar with CVR - He describes how distressed biotech deals may monetize assets while preserving upside via contingent value rights Regulatory/market environment: High equity volatility, high unstable rates, tight financing - He says current conditions are rough for many event-driven deals Burford-related claim: Peterson claims against Argentina - Chris says he is a claimant and also an equity holder in Burford Timeframe for more visibility on Burford/Argentina: Over the next year - He expects more clarity on settlement and resolution within a year Biotech example: Keros Therapeutics - Discussed as a potential strategic-review / monetization case

Pivotal Quotes: "finish the sentence. Just tell me why. And once I'm convinced, I'll immediately do what you say." — Chris Timo Jr.: Describing his childhood instinct for demanding reasons before accepting authority or convention "I want to know about the local knowledge, even though it doesn't always occur to people how special the thing is, because it's not, it's just the most ordinary thing to him." — Chris Timo Jr.: Explaining why he prefers direct, insider knowledge over broad macro commentary "you need to enjoy edges and advantage plays when you have them. But one sure sign that you were really onto something is when it goes away" — Chris Timo Jr.: On how real strategy edges erode as markets become more efficient and competitive

Implications: Listeners should expect event-driven investing to rely more on deep research, local expertise, and disciplined sizing than on simple arbitrage formulas. In today’s market, patience, shareholder activism, and capital-return pressure may be key in distressed biotech and litigation situations.